MVRx To Present Outcomes Of Global Clinical Trials For ARTO System At EuroPCR-2017 – May 16-17

SAN MATEO, Calif.--(BUSINESS WIRE)--More than three years after launching human trials – now spanning four continents and 15 centers of excellence – MVRx is set to announce final outcomes of its Phase 1 MAVERIC trial for the ARTO System at the annual global forum for interventional cardiovascular medicine, to be held at the Palais des Congrès in Paris, France from May 16 – 19, 2017.

"Presenting successful results at EuroPCR is a major milestone in our development,” says Robert Chang, president and chief executive officer of the San Mateo, California-based medical device startup.

More than 12,000 participants from around the world will have several distinct opportunities to learn about the MVRx ARTO System and its effectiveness in TART (Transcatheter Annular Reduction Therapy):

Oral Presentation: Three-year Final Outcomes of the Phase 1 MAVERIC Trial Using the ARTO System for the Treatment of Functional Mitral Regurgitation
Tuesday, May 16
13:00 – 13:08
Presenter: Andrejs Erglis, MD, PhD
Location: Room 242B

Oral Presentation: The mitral valve repair clinical (MAVERIC) trial
Tuesday, May 16
14:40 – 14:48
Presenter: Stephen Worthley, MD, PhD
Location: CV Pipeline Session, Room 351

Sponsored Symposium: Transcatheter Annular Reduction Therapy (TART) for Functional Mitral Regurgitation: An Introduction to the ARTO System
Wednesday, May 17
12:30 – 13:30
Chairmen: David Hildick-Smith, MD and Andrejs Erglis, MD, PhD
Presenters: Bernard Prendergast, MD; Simon Redwood, MD; Stephen Worthley, MD, PhD; and Jason H. Rogers, MD
Location: Room 352 B

About MVRx – We are researchers, engineers and developers with deep medical device expertise, working to improve the quality of life for people living with heart failure-related mitral valve regurgitation. For more information, please visit www.mvrxinc.com.

The ARTO System for Transcatheter Annular Reduction Therapy (TART) – our simple, one size technology to treat functional mitral regurgitation – reduces the AP mitral annular diameter and mitral regurgitation without compromising the coronary arteries. Clinical trials occur on four continents and 15 centers of excellence in the UK, Italy, France, Latvia, South Africa, Australia and the U.S.